Representative before the EPO

Employment test 11 - 50 employees
Company dna eip1
operating since 2009
1147.36
Headquarter in London and 4 offices
active in Legal Services and IP Consulting

We have observed 4 EP applications Andrew John Sharples has served for within the last five+ years. (We consider all applications which have an EP A1 or A2 publication dated after December 02, 2013). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP12718709

PYRROLIDINE DERIVATIVES AS SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF

IPC classification:
A61K 31/401, A61K 31/40, C07D 207/16, C07D 207/12, A61P 37/00, A61P 25/28, A61P 11/06, A61P 9/10
Agent:
Andrew John Sharples, EIP Europe LLP
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12716750

METHODS FOR PREPARATION OF MACROCYCLIC POLYESTER OLIGOMER VIA HETEROGENEOUS CATALYSIS

IPC classification:
C08G 63/85, C08G 63/81, C08G 63/183, B01J 37/02, B01J 21/08, B01J 21/06
Agent:
Andrew John Sharples, EIP Europe LLP
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP13746382

COLD BLOCK WITH EMBEDDED CHAMBERED BEVERAGE TAP

IPC classification:
B67D 1/04
Agent:
Andrew John Sharples, EIP Europe LLP
Status:
The patent has been granted
EP12704188

USE OF GALECTIN-3 FOR DETECTING AND PROGNOSING HEART FAILURE AFTER ACUTE CORONARY SYNDROME

IPC classification:
G01N 33/68, G01N 33/566
Agent:
Andrew John Sharples, EIP Europe LLP
Status:
APPLICATION DEEMED TO BE WITHDRAWN

Please Sign in to use this feature